CAMP NASDAQ
CAMP4 Therapeutics Corporation
1W: +2.0%
1M: +5.3%
3M: -6.5%
YTD: -33.3%
1Y: +35.6%
$4.00
+0.16 (+4.17%)
Weekly Expected Move ±8.9%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$251.0M
52W Range2.86-7.75
Volume367,956
Avg Volume248,509
Beta0.21
Dividend—
Analyst Ratings
Company Info
CEOJoshua Mandel-Brehm
Employees48
SectorHealthcare
IndustryBiotechnology
IPO Date2024-10-11
Websitecamp4tx.com
One Kendall Square Bldg 1400 West, 3rd Floor
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617-651-8867
About CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Latest News
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages
Brokerages Set CAMP4 Therapeutics Corporation (NASDAQ:CAMP) PT at $9.56
BlackRock Inc. Purchases New Position in CAMP4 Therapeutics Corporation $CAMP
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives $8.36 Average PT from Brokerages
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gold Kelly | P-Purchase | 10,000 | $3.96 | 2026-08-31 |
| Schwab Andrew J. | S-Sale | 400,000 | $4.04 | 2026-08-27 |
| Schwab Andrew J. | S-Sale | 10 | $4.50 | 2026-08-24 |
| Schwab Andrew J. | S-Sale | 32,018 | $4.50 | 2026-08-21 |
| Schwab Andrew J. | S-Sale | 114,700 | $4.54 | 2026-08-20 |